A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.

A recap of business developments from life sciences companies around the world, including U.K.-based Vaccitech Limited and the University of Oxford touting positive safety and efficacy trends in a mid-stage prostate cancer study.

AbbVie Inc., along with Teneobio Inc. and that company’s affiliate TeneoOne Inc., announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.

Boehringer Ingelheim exercised an option to buy an EMBL Ventures portfolio company, ViraTherapeutics.